Evidence map›Paper›PMID 40059770›Full record

ArticleEmerging microbes & infections2025

CpG oligodeoxynucleotides and pan-serotype inhibitors control neurotropic dengue infection in novel immune competent neonatal mouse model.

Mirian Mendoza, Derek D C Ireland, Ha-Na Lee, Logan Kelly-Baker, Monica Chowdhury, Daniela Verthelyi, Mohanraj Manangeeswaran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mirian MendozaOffice of Pharmaceutical Quality Research, Division IV, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Derek D C IrelandOffice of Pharmaceutical Quality Research, Division IV, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Ha-Na LeeOffice of Pharmaceutical Quality Research, Division IV, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Logan Kelly-BakerOffice of Pharmaceutical Quality Research, Division IV, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Monica ChowdhuryOffice of Pharmaceutical Quality Research, Division IV, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Daniela VerthelyiOffice of Pharmaceutical Quality Research, Division IV, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.ORCID 0000-0002-5450-3071
Mohanraj ManangeeswaranOffice of Pharmaceutical Quality Research, Division IV, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue virus (DENV) is a growing global public health threat. The lack of symptomatic immune-competent animal models for dengue has hindered the screening and development of effective therapeutics that can be used to control dengue virus replication and thereby control the progression to severe dengue disease. To address this, we established an infection model in neonatal C57BL/6 mice and showed that a systemic Dengue challenge leads to ataxia, seizures, paralysis, and death within 15 days. The virus was found predominantly in the eye and brain where DENV infects neurons but not astrocytes and causes extensive infiltration of macrophages and microglia activation. The response to infection included upregulation of multiple genes linked to interferons (

Indexed as

Antiviral AgentsDengueDengue VirusOligodeoxyribonucleotidesAnimalsAnimals, NewbornBrainDisease Models, AnimalHumansMiceMice, Inbred C57BLSerogroupVirus ReplicationAntiviral AgentsCPG-oligonucleotideOligodeoxyribonucleotidesDengueimmunocompetentimmunomodulatorymouse modelneurotropicvirus

Identifiers

PMID40059770
PMCPMC12269057

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.